CID 16020046 NEW
| Price | $33 | $56 | $81 |
| Package | 2mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: CID 16020046 | CAS No.: 834903-43-4 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | CID 16020046 |
| Description | CID 16020046 (C390-0219) is a selective GPR55 antagonist, inhibiting GPR55 constitutive activity with IC50 of 0.15 μM in yeast. |
| In vitro | In yeast cells expressing human GPR55, CID16020046 inhibited agonist-induced receptor activation. In human embryonic kidney (HEK293) cells stably expressing human GPR55, CID16020046 behaved as an antagonist on LPI-mediated Ca2+ release and extracellular signal-regulated kinases activation, but not in HEK293 cells expressing cannabinoid receptor 1 or 2 (CB1 or CB2). CID16020046 dose-dependently inhibited lysophosphatidylinositol (LPI)-induced activation of nuclear factor of activated T-cells (NFAT), nuclear factor κ of activated B cells (NF-κB) and serum response element, translocation of NFAT and NF-κB, and GPR55 internalization [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (23.51 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (23.51 mM), Solution. DMSO : 125 mg/mL (293.81 mM), Sonication is recommended. |
| Keywords | wound | platelet | phosphorylation | m-opioid | lysophosphatidylinositol | LPI | KCNH2 | Inhibitor | inhibit | HMVEC | hERG | HEK | healing | GPR55 | G protein-coupled receptor 55 | function | ERK1/2 | endothelial | CID-16020046 | CID16020046 | CID 16020046 | cells | CannabinoidReceptor | Cannabinoid Receptor | Ca2+ | acetylcholinesterase |
| Inhibitors Related | RTICBM-189 | β-Caryophyllene | CB2 modulator 1 | Pregnenolone | CB1 inverse agonist 1 | Pregnenolone acetate | CB1 antagonist 2 | CB2 receptor agonist 2 | AM-1235 | 2,3-Butanediol | Drinabant | AM281 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | NO PAINS Compound Library | Endocrinology-Hormone Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 | ||
| $5.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-09-04 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY